Colonscopia Virtuale

Colonscopia Virtuale
BIBLIOGRAFIA
[1] McGuire WP, Hoskin WJ, Brady MF, Kucera PR, Patridge EE, Look KY, Clarke-Pearson D.L, Davidson M: Cyclophosphamide and Cisplatin compared with Paclitaxel and cisplatin in Patients with Stage III and IV Ovarian Cancer. N Engl J Med, 334: 1-6, 1996.
[2] Conte PF, Gadducci A, Cianci C.  Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer. 2001;11 Suppl 1:52-6.
[3] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59.
[4] Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol; 47(2):159-66 1992.
[5] Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery Is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: prospective study. Gynecol Oncol 69:103-108, 1998
[6] Heintz APM, van Oostrom AT, Trimbos JBMC, et al.: The treatment of advanced ovarian carcinoma.I. Clinical variables associated with prognosis. Gynecol Oncol 30:348-358, 1988.
[7] Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma. Gynecol Oncol 1997 67:208-214.
[8] Bertelson K: Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990 38:203-209.
[9] Eisenkop SM, Spirtos NM, Montag TW, Nalick RH Wang HW. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992 47:203-209.
[10] LoCoco S, Covens A, Carney M, Franssen E, Dogde R, Rosen B, Osborne R, Kerr I, Buckman R, Soper J, et al.. Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 1995 Nov;59(2):194-9.
[11] Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, van Lindert AC, Hamerlynck JV, van Lent M, van Houwelingen JC, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984 Sep 15;2(8403):594-600.
[12] Michel G, De iaco P, Castaigne D, El-Hassan MJ, Lobreglio R, Lhomme C, Rey A, Duvillard P: Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynecol Oncol 18:9-15, 1997.
[13] Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990 Nov;39(2):115-8.
[14] Deppe G, Malviya VK, Boike G, Malone JM Jr. Use of Cavitron surgical aspirator for debulking of diaphragmatic metastases in patients with advanced carcinoma of the ovaries. Surg Gynecol Obstet 1989 May;168(5):455-6.
[15] Rose PG.The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992 Mar;166(3):843-6.
[16] Benedetti-Panici P, Maneschi F, Scambia G, Cutillo G, Greggi S, Mancuso S. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstet Gynecol 1996 Apr;87(4):532-8.
[17] Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA.  Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004; 11:178-86.
[18] Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006 Mar 1;106(5):1144-53.
[19] Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH.  Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999 Dec;6(8):790-6.
[20] Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003 Oct;10(8):863-9.
[21] Eisenkop SM and Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82:435-441, 2001.
[22] Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, Dematteo RP, D'Angelica MI, Barakat RR, Chi DS. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006 Aug 2; [Epub ahead of print]
[23] De Gramont A, Drolet Y, Varette C, Louvet C, Gonzalez-Canall G, Krulik M, Cady J, Pigne A, Marpeau L, Barrat J, Gallot D, Malafosse M, Debray J: Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur J. Cancer Clin Oncol, 25: 451-457, 1989.
[24] Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards C.L, Rutledge FN: Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer, 5: 1129-1135, 1985.
[25] Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, Malkasian GD, Stanhope CR, Wilson TO. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol. 1988 Sep;31(1):9-24.
[26] Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, Markman M, Hakes T, Reichman B, Jones WB, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol. 1989 Sep;34(3):365-71.
[27] Williams L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 1997 Aug;66(2):171-8.
[28] Obermaier A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand. 2001 May;80(5):432-6.
[29] Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004 Nov;95(2):273-80. Review.
[30] Salom E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol. 2002 Sep;14(5):519-27. Review.
[31] Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006 May 1;106(9):1933-9.
[32] ten Bokkel Huinink WW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Dawidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol, 15: 2183-2193, 1997.
[33] Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22.
[34] Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005 Apr;97(1):74-9.
[35] Markman M, Kelsen D: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118:547-550, 1992.
[36] Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5.
[37] Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7
[38] National Cancer Institute.: NCI Clinical Announcement on Intraperitoneal Chemotherapy for Ovarian Cancer (January 5, 2006). Rockville, Md: Cancer Therapy Evaluation Program, NCI, 2006 Available online. Last accessed April 26, 2006.
[39] Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1999; 7: 83±90.
[40] Dahl O, Dalene R, Schem BC, Mella O. Status of clinical hyperthermia. Acta Oncol 1999; 38: 863±873.
[41] Roca C, Primo L, Valdembri D, Cividalli A, Declerck P, Carmeliet P, Gabriele P, Bussolino F. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res. 2003 Apr 1;63(7):1500-7. Erratum in: Cancer Res. 2003 May 1;63(9):2345.
[42] Calderwood SK, Hahn GM Thermal sensitivity and resistance of insulin-receptor binding. Biochim Biophys Acta 1983 Mar 15;756(1):1-8.
[43] DuBose DA, Hinkle JR, Morehouse DH, Ogle PL: Model for environmental heat damage of the blood vessel barrier. Wilderness Environ Med 1998; 9: 130-136.
[44] Xu M, Myerson RJ, Straube WL, Moros EG, Lagroye I, Wang LL, Lee JT, Roti Roti JL. Radiosensitization of heat resistant human tumour cells by 1 hour at 41.1 degrees C and its effect on DNA repair. Int J Hyperthermia 2002 Sep-Oct;18(5):385-403.
[45] Vaupel PW. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin Padiatr 1997 Jul-Aug;209(4):243-9.
[46] Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin N America 1989; 27: 621±627.
[47] Engelhardt R: Hyperthermia and drugs. Recent Results Cancer Res 104:136-203, 1987.
[48] Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC: Enhancement By hyperthermia of the in vitro cytotoxicity of Mitomycin C toward hypoxic tumor cells. Cancer Res 41:1096-1099, 1981.
[49] Vaart PJM, Vange N, Zoetmulder FAN, Goethem AR, Tellingen O, Huinink, B Beijnen JH, Bartelink H and Begg AC. Intraperitoneal Cisplatin with Regional Hyperthermia in Advanced Ovarian Cancer: Pharmacokinetics and Cisplatin-DNA Adduct Formation in patients and Ovarian Cancer Cell Lines. Eur J Cancer 34:148-154, 1998.
[50] Hettinga JVE, Lemstra W, Meijer C, Dam WA, Uges DRA, Konings AWT, Vries EGE and Kampinge HH: Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells. Br J Cancer 75:1735-1743, 1997.
[51] Bull JMC. An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res 1984; 44: 4853s±4856s.
[52] Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 2005 Feb;96(2):301-6.
[53] Sugarbaker P.H. Peritonectomy procedures. Annals of surgery, 221(1):29-42, 1995.
[54] Sugarbaker PH. Laser-mode electrosurgery. Cancer Treat Res. 1996;82:375-85.
[55] Paul H. Sugarbaker. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. In: Paul H. Sugarbaker, ed. Paul H. Sugarbaker. Peritoneal Carcinomatosis: Drugs and Diseases. Kluwer Academic Publishers. Boston/Dordrecht/London 1996: 75-87.
[56] Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80.
[57] Eisenkop SM, Spirtos NM, Lin WC. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol. 2006 Oct;103(1):329-35. Epub 2006 Jul 31.
[58] Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin N Am. 2003 Jul;12(3):561-83.
[59] Jacquet P, and Sugarbaker PH: Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49-58, 1996.
[60] Vaart P.J.M., Vange N., Zoetmulder F.A.N., Goethem A.R., Tellingen O., ten Bokkel Huinink W.W., Beijnen J.H., Bartelink H., Begg A.C.: Intraperitoneal Cisplatin with Regional Hyperthermia in Advanced Ovarian Cancer: Pharmacokinetics and Cisplatin-DNA Adduct Formation in patients and Ovarian Cancer Cell Lines. Eur. J. Cancer., 34: 148-154, 1998.
[61] van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, ten Bokkel Huinink WW, Beijnen JH. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000 Nov;26(7):663-8.
[62] Steller M.A., Egorin M.J., Trimble E.L., Bartlett D.L., Zuhowski E.G., Alexander H.R., Dedrick R.L.: A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother. Pharmacol., 43: 106-114, 1999.
[63] Nicoletto MO, Padrini R, Galeotti F, Ferrazzi E, Cartei G, Riddi F, Palumbo M, De Paoli M, Corsini A. Pharmacokinetics of Hyperthermic intraperitoneal chemotherapy with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000;45:457-462.
[64] Rufian S, Munoz-Casares FC, Briceno J, Diaz CJ, Rubio MJ, Ortega R, Ciria R, Morillo M, Aranda E, Muntane J, Pera C. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006 Sep 15;94(4):316-24.
[65] Deraco M., Rossi C.R., Pennacchioli E., Guadagni S., Somers D.C., Santoro N., Raspagliesi F., Kusamura S., Vaglini M. Cytoreductive surgery followed by Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori, 87(3):120-126, 2001.
[66] de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res. 2003 May-Jun;23(3C):3019-27.
[67] Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, Kim SJ, Lee JM. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Aug;94(2):325-32.
[68] Cohen CJ. Surgical considerations in ovarian cancer. Semi Oncol 1985,12,53-6.
[69] Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-41.
[70] ten Bokkel Huinink WW, Heintz APM, Dubbelman R, Franklin H, Mcvie JG. Intraperitoneal carboplatina for refractory ovarian cancer: phase I study. Proceedings of the Second International Conference of intracavitary Chemotherapy, p.47, San Diego, 1988.
[71] Pfeiffer P, Bennendbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990,36,306-311.
[72] Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998;41(2):147-54
[73] Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979 Aug;39(8):3209-14.
[74] Ozols RF, Young RC, Speyer JL et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancers. Cancer Res 1982, 42, 4265-9.
[75] Los G, Mutsaers PH, Ruevekamp M, McVie JG. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett 1990 May 30;51(2):109-17.
[76] Haveman J, Rietbroek RC, Geerdink A, Van Rijn J, Bakker PJ. Effect of hyperthermia on the cytotoxicity of 2',2'-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 1995 Sep 4;62(5):627-30.
[77] Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F, Younan R, Baratti D, Mariani L, Laterza B, Deraco M. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006 Aug;32(6):671-5. Epub 2006 Apr 18.
[78] Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Hyperthermic intraperitoneal chemotherapy chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001;11 Suppl 1:57-63.
[79] Piso P, Dahlke MH, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol. 2004 Jun 28;2(1):21.
[80] Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, Bruno F, De Riu L, Airoldi M, Pedani F. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004 Oct;28(10):1040-5.
[81] Gori J, Castano R, Toziano M, Habich D, Staringer J, De Quiros DG, Felci N. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9.
[82] Raspagliesi F, Deraco M, Rossi CR. Stage III / IV epithelial ovarian cancer with macroscopic residual disease after 1st line Chemotherapy: a multicentric prospective randomised study comparing loco regional approach + systemic chemotherapy vs systemic chemotherapy alone. http://www.sitilo.org.

 

 

References

1. Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203.
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7.
4. Karlan By, Markamn MA, Eifel PJ: Ovarian cancer peritoneal carcinoma and fallopian tube carcinoma. DE Vita, Hellman, Rosemberg: Cancer: Principles and practice of oncology. Ed. Lippincott Williams and Wilkins 7th edition 2005.
5. Conte PF, Gadducci A, Cianci C, et al. Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer. 2001;11 Suppl 1:52-6. Review.
6. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91.
7. De Gramont A, Drolet Y, Varette C, et al. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur J Cancer Clin Oncol. 1989 Mar;25(3):451-7.
8. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000 Jan;18(1):106-15.
9. Diaz-Montes TP, Bristow RE. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep. 2005 Nov;7(6):451-8. Review.
10. Santillan A, Karam AK, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007 Mar;104(3):686-90. Epub 2006 Dec 1.
11. Surgical resections of tumour bulk in the primary treatment of ovarian carcinoma. NCI monogr. 1975;42:101-4.
12. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983 Apr;61(4):413-20.
13. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80.
14. Eisenkop SM, Friedman RL, Wang HJ, et al. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998 May;69(2):103-8.
15. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59.
16. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995 Jan;221(1):29-42.
17. Vasquez V de L, Sugarbaker PH. Total anterior parietal peritonectomy. J Surg Oncol. 2003 Aug;83(4):261-3.
18. Sugarbaker PH. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol. 2001 Dec; 31(12):573-83.
19. Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003 Jul; 83(3):147-53.
20. DeracoM, Daratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004 Apr;11(4):393-8.
21. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004 Aug 15;22(16):3284-92.
22. Glehen O, Mohamed F, Gilly FN, et al. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004 Apr;5(4):219-28.
23. Hadi R, Saunders V, Utkina O, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg. 2006 Mar;76(3):156-61.
24. van der Vange N, van Goethem AR, Zoetmulder FA, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol. 2000 Nov;26(7):663-8.
25. Chatzigeorgiou K, Economou S, Chrysafis G, et al. Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Zentralbl Gynakol. 2003 Oct;125(10):424-9.
26. Piso P, Dahlke MH, Loss M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer.
World J Surg Oncol. 2004 Jun 28;2(1):21.
27. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg. 2004 Oct;28(10):1040-5.
28. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41.
29. Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Aug;94(2):325-32.
30. Gori J, Castano R, Toziano M, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9.
31. Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006 Aug;32(6):671-5.
32. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006 Sep 15;94(4):316-24.
33. World health organization: WHO handbook for reporting results of cancer treatment. World health organization Geneva 1979.
34. Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal Carcinomatosis. Sugarbaker PH editor “Peritoneal carcinomatosis: principles of management” – BOSTON, Kluwer Academic Publishers 1996 p. 359-74.
35. AJCC Cancer staging handbook: TNM classification of malignant tumors. Sixth edition Springer 2002.
36. Sugarbaker PH editor “Peritoneal carcinomatosis: principles of management” – BOSTON, Kluwer Academic Publishers 1996.
37. Bozzetti F, Braga M, Gianotti L, et al. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet. 2001 Nov 3;358(9292):1487-92.
38. Deraco M, Raspagliesi F, Kusamura S, et al. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin N Am. 2003 Jul;12(3):561-83.
39. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001 Sep;82(3):532-7.
40. Stoeckle E, Paravis P, Floquet A, et al. Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):779-87.
41. Eisenkop SM, Freidman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88:145-153.
42. Dauplat J, Le Bouedec G, Pomel C, et al. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000; 19:42-48.
43. Eisenkop SM, Spirtos NM Friedman RL, et al. Relative influences of tumour before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003; 90:390-396.
44. Chi DS, Franklin CC, DA Akselrod F, et al. Improved optimal cytoreduction rates for stages III C and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a chance in surgical approach. Gynecol Oncol 2004; 94:650-654.
45. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 2004; 100:1152-1161.
46. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007; 109(4):685-691.
47. Gomez Portilla A, Sugarbaker PH, Chang D. Second look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999; 23:23-29.
48. Berthet B, Sugarbaker TA, Chang D, et al. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999; 35:413-419.
49. Elias D, Blot F, El Otmany A. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 91:71-76.
50. Da Silva RG, Sugarbaker PH. Analysis of prognostic factors in severity patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006; 203:878-886.
51. Le T, Krepart GW, Lotocki RJ, et al. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecol Oncol 1997; 67:208-214.
52. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with biological aggressiveness and survival?. Gynecol Oncol 2001; 82:436-441.
53. Goldie GH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Canc Treat Rep 1979; 63:1727-1733.
54. Markman M, BelinsonJ. A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non surgically respectable ovarian or primary peritoneal cancers. J Cancer Res Clin Oncol 2005; 131:26-30.
55. Pecorelli S, Odicino F, FavalliG. Interval debulking surgery in advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002; 16:573-583.
56. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11:166-172.
57. Bristow RE, Duska LR, Lambrou NC, et al. A model for prediction surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000; 89:1532-1540.
58. Funt SA, Hricak H, Abu-Rustum N, et al. Role of CT in the management of recurrent ovarian cancer. Am J Roentgenol 2004; 182:393-398.
59. Obeidat B, Latimer J. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer?. Gynecol Obset Invest 2004; 57:153-156.
60. Berchuck A, Iversen S, Lancaster J, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use microarrays. Am J Obstet Gynecol 2004; 190:910-925.
61. Dowdy S, Mullany S, Brandt K, et al. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004; 101(2): 346-352.
62. Gemer O, Lurian M, Gdavelich M, et al. A multicenter study of ca125 as a predictor of non optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 2005; 31:1006-1010.
63. Angioli R, Paldia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 2006; 100: 455-461.
64. Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 2006; 16(suppl 1): 35-40.
65. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006; 367:1558-1560.
66. Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104:480-490.
67. Eisenkop SM, Nalick RM, Teng NNM. Modified posterior exenteration for ovarian cancer. Obstetrics and gynecology 1991; 78:879-885.
68. Sugarbaker PH. Complete parietal and visceral Peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Peritoneal carcinomatosis: drug and disease. Kluwer Academic publisher 1996; 75-87.
69. Nicklin JL, Copeland LJ, O’Toole RV. Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 1995; 58:244-247.
70. Chen LM, Karlan BJ. Recurrent ovarian carcinoma: is there a place for surgery? Seminars in Surgical Oncology 2000; 19:62-68.
71. Ayhan A, Baykal AC, Demirtas E, et al. The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14:51-56.
72. Chi DS, Fong Y, Venkatraman ES, et al. Hepatic resection for metastatic gynecologic carcinomas. Gynecol Oncol 1997; 66:45-51.
73. Bristow RE, Montz FJ, Lasasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72:278-287.
74. Curtin JP, Mauk R, Venkatraman ES, et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997; 64:9-13.
75. Glemen O. Hyperthermic intraoperative chemotherapy: nomenclature and modality of perfusion. 5th International workshop on peritoneal surface malignancy. Scientific documents and abstract p17 Milan December 4th-6th 2006.
76. Loggie BW, Fleming RA, McQuellon RP, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated cancer of gastrointestinal origin. Am Surg 2000; 66(6):561-568.
77. Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attemped cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91:747-754.
78. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of  monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48:7022-7032.
79. Leunig M, Goetz AE, Dellian M, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992; 52(2): 487-490.
80. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999; 44(5):1111-23.
81. Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001; 87(3):120-26.
82. Heinz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6(1):107-138.

 
Infolabio